Posted by Michael Wonder on 08 Aug 2018
The FDA is poised to approve the first-ever drug that mutes disease-causing genes
7 August 2018 - After a decades-long wait, the FDA is on the brink of approving a landmark rare disease treatment — the first to rely on a Nobel prize-winning technique known as RNA interference, or RNAi.
The widely anticipated approval will be a watershed moment not only for its manufacturer, Alnylam, but for the broader field of research into RNAi, which lets scientists mute genes that aren’t functioning properly.
The FDA must announce its decision by Friday to meet a a regulatory deadline.
